Past, present and future targets for immunotherapy in ovarian cancer. (December 2014)

• Record Type: Journal Article
• Authors: Schwab, Carlton L; English, Diana P; Roque, Dana M; Pasternak, Monica; Santin, Alessandro D
• Is Part Of: Immunotherapy. Volume 6:Number 12(2014:Dec.)
• Page Start: 1279
• Page End: 1293
• Publication Date: 2014-12
• Subjects: adoptive transfer -- CA125 -- EpCAM -- mesothelin -- NY-ESO-1 -- ovarian cancer -- p53 -- tumor associated antigens -- tumor vaccines -- WT-1; Immunotherapy -- Periodicals; 615.37
• DOI: 10.2217/imt.14.90
• Languages: English
• ISSNs: 1750-743X

Abstract

Ovarian cancer is the leading cause of death from gynecologic malignancy in the US. Treatments have improved with conventional cytotoxic chemotherapy and advanced surgical techniques but disease recurrence is common and fatal in nearly all cases. Current evidence suggests that the immune system and its ability to recognize and eliminate microscopic disease is paramount in preventing recurrence. Ovarian cancer immunotherapy is targeting tumors through active, passive and adoptive approaches. The goal of immunotherapy is to balance the activation of the immune system against cancer while preventing the potential for tremendous toxicity elicited by immune modulation. In this paper we will review the different immunotherapies available for ovarian cancer as well as current ongoing studies and potential future directions.